Pharmaceuticals, Biotechnology and Life Sciences
Actinium highlighted high rates of Complete Remission (CR/CRi) and rates of measurable residual disease (MRD) negativity with improved overall survival…
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) and Immedica Pharma AB (“Immedica”)have entered a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.
Actinium Pharmaceuticals has reported 67% overall response rate in first cohort in Actimab-A Venetoclax combination trial in relapsed and refractory AML at ASH, which includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of Actimab-A indicative of mechanistic synergy with venetoclax.
Actinium Pharmaceuticals on Wednesday announced the pricing of its previously announced public offering with gross proceeds expected to be approximately $25.0 million.
Actinium Pharmaceuticals is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.
Actinium Pharmaceuticals on Monday announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B at 50% of total of 150-patient, compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML (Acute Myeloid Leukemia).
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.
Actinium Pharmaceuticals has appointed Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain, who will also serve as a member of Actinium’s executive leadership team.
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM